Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Clinical Evaluation of Bioflx Crowns in Restoring Primary Anterior Teeth

NCT07883187 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11-09
Last updated
2026-10-20

Condition(s) studied

ClinicalPrimary TeethRestorationCrown

Investigational drug(s) / intervention(s)

Bioflx Crown Restoration (Group I)Celluloid Strip Crown Restoration (Group II)

Bioflx Crown Restoration (Group I): Preparation: Administration of 2% lidocaine local anesthesia with epinephrine; caries removal; 1-1.5 mm incisal reduction; 1 mm mesial/distal contact breaking using diamond burs; minimal labial/palatal reduction; rounding of sharp line angles. Seating \& Cementation: Selection of appropriate Bioflx crown size via mesiodistal caliper measurement; crown try-in; cavity sealing and final cementation using self-curing glass ionomer cement (IMICRYL Nova); excess cement removal with explorer and dental floss.

Celluloid Strip Crown Restoration (Group II): Preparation: Local anesthesia administration; caries removal; shade selection; incisal and proximal reduction. Matrix \& Bonding: Celluloid strip crown form selected, trimmed to length, verified for cervical adaptation, and vented at the incisal edge. Enamel etched with 37% phosphoric acid (CharmEtch) for 15 seconds, rinsed, and dried. Universal bonding agent (All-Bond Universal) applied and light-cured for 15 seconds. Placement \& Finishing: Crown form filled with shade-matched composite resin (Beautifil), seated firmly on the tooth, excess material removed, and light-cured. Celluloid form stripped off using an excavator; final polishing performed.

Study summary

This randomized controlled clinical trial evaluates and compares the clinical success and performance of prefabricated Bioflx crowns versus conventional Celluloid strip crowns in the restoration of badly decayed or traumatized primary anterior teeth.

Eligibility

Sex
ALL
Min age
3 Years
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Healthy children aged 3-5 years with cooperative behavior (Frankl's behavior rating scale 3-4). * Bilateral anterior primary teeth affected by multi-surface caries requiring full coronal restoration. * At least two-thirds of the root structure is present, and adequate coronal tooth structure to retain the crown. Exclusion Criteria: * Non-restorable teeth * Teeth with single-surface restorations. * Previous full-coverage restoration or large unsuccessful restoration on the target tooth. * Children with oral parafunctional habits (e.g., thumb sucking, bruxism). * Advanced physiologic root resorption (\>1/3).

Primary outcome measure(s)

  • Restoration Clinical Performance (Modified USPHS Criteria) — Evaluated at 3, 6, and 9 months post-operative.
    Measure Description: Visual, explorer, and dental floss evaluation of four distinct clinical parameters scored as Alpha (A), Bravo (B), Charlie (C), or Delta (D): Marginal Integrity: Alpha (close adaptation), Bravo (explorer catches), Charlie (defect extending to dentin). Color Match: Alpha (exact match in shade/translucency), Bravo (mismatch within normal tooth range), Charlie (mismatch outside normal range). Restoration Integrity / Failure Rate: Alpha (normal, no chip/fracture), Bravo (small material loss), Charlie (large material loss), Delta (complete crown loss). Proximal Contact: Alpha (resistance to floss), Bravo (floss passes without resistance), Charlie (no contact).

Trial sites (1)

FacilityCityRegionStatus
faculty of dentistry, Tanta university Tanta Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07883187 on ClinicalTrials.gov ↗ ← All trials in Egypt